Glioma Drug Profiles and Clinical Trials - Global Trends and Analysis Review, H1 2018

  • ID: 4460269
  • Report
  • Region: Global
  • 540 Pages
  • VPA Research
10 % OFF
until Nov 30th 2018
1 of 4
This Research Analyzes the Evolution of Glioma Clinical Trial Trends Across Countries and Regions

Glioma clinical trials report from this research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report along with their details of mechanism of action, route of administration, target, therapy, molecule and class.

Scope of the Report:

  • Number of Glioma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Glioma
  • Both observational and interventional trials analyzed
  • Success rates of trials are analyzed
  • Trends in enrollment over the past ten years identified
  • Leading sponsors of Glioma clinical trials worldwide are listed

Reasons to Buy:

  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market

Glioma- The condition occurs when the glial cells in the brain are affected and account for around one-third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).

On the basis of pace of development, these are categorized as low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.

Malignant Glioma- Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high-grade gliomas and glioblastomas respectively.

High Grade Glioma- Malignant or high-grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include-

Anaplastic astrocytoma- The rare disease type comprises an estimated one-third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.

Anaplastic oligodendroglioma- It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.

Anaplastic oligoastrocytoma- Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.

Anaplastic ependymoma- The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.

Glioblastoma- The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.

Pontine Gliomas- Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.

Low Grade Glioma (LGGs) or often referred to as Grade-1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.

On the basis of appearance under microscope and genetic modifications, low grade gliomas are classified as-
Pilocytic astrocytomas - Observed in adults aging less than 25 and progresses very slowly compared to other types

Diffuse astrocytomas - Most observed subtype of low-grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate-dehydrogenase gene determines the sub-types of Diffuse astrocytomas.

Oligodendrogliomas - Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.

Gangliogliomas - Posesses both gliomas and tumor related characteristics.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

1.1. List of Figures
1.2. List of Tables

2. Executive Summary:

  • 2.1 Report Guide
  • 2.2 Key Findings
  • Overview of Global Clinical Trials Initiated in 2017
  • Average Enrolment by Country, 2010 - 2017
  • Prominent Companies in Global Glioma Trials, 2010 - 2017

3. Glioma Drugs in Ongoing and Completed Trials:

  • 3.1 Prominent Drugs in Development and Approved Stages for Glioma
  • 3.2 Glioma Product Snapshots
  • Glioma Drug Profiles

4. Global Glioma Clinical Trial Research Trends:

  • 4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
  • Clinical Trials by Country
  • Number of Ongoing/Planned Trial Locations in Each Country
  • 4.2 SUBJECTS RECRUITED BY TOP 10 COUNTRIES, 2010 - 2017
  • Total Enrolment by Country
  • 4.3 Clinical Trials by Region, 2010 - 2017
  • 4.4 Subjects Recruited by Region, 2010 - 2017
  • 4.5 Clinical Trials by Year, 2010 - 2017
  • 4.6 Subjects Recruited by Year, 2010 - 2017
  • 4.7 Clinical Trials by Development Phase, 2010 - 2017
  • Clinical Trials by Phase
  • 4.8 Subjects Recruited by Development Phase, 2010 - 2017
  • 4.9 Clinical Trials by Status, 2010 - 2017
  • 4.10 Subjects Recruited by Trial Status, 2010 - 2017
  • 4.11 Clinical Trials by Sponsor Type, 2010 - 2017
  • 4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
  • 4.13 Clinical Trials by Economy Type, 2010 - 2017

5. Europe Glioma Clinical Trial Research Trends:

  • 5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
  • Europe, Clinical Trials by Country
  • 5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
  • Europe, Total Enrolment by Country
  • 5.3 Europe, Clinical Trials by Year, 2010 - 2017
  • 5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
  • 5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
  • 5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6. Eastern Mediterranean Glioma Clinical Trial Research Trends

7. South East Asia Glioma Clinical Trial Research Trends

8. North America Glioma Clinical Trial Research Trends:

  • 8.1 Clinical Trials by Top Countries in North America, 2010 - 2017
  • North America, Clinical Trials by Country
  • 8.2 Subjects Recruited by Top Countries in North America, 2010 - 2017
  • North America, Total Enrolment by Country
  • 8.3 North America, Clinical Trials by Year, 2010 - 2017
  • 8.4 North America, Clinical Trials by Development Phase, 2010 - 2017
  • 8.5 North America, Clinical Trials by Trial Status, 2010 - 2017
  • 8.6 North America, Clinical Trials by Sponsor Type, 2010 - 2017

9. South and Central America Glioma Clinical Trial Research Trends:

  • 9.1 Clinical Trials by Top Countries in South And Central America, 2010 - 2017
  • South and Central America, Clinical Trials by Country
  • 9.2 Subjects Recruited by Top Countries in South and Central America, 2010 - 2017
  • South and Central America, Total Enrolment by Country
  • 9.3 South and Central America, Clinical Trials by Year, 2010 - 2017
  • 9.4 South and Central America, Clinical Trials by Development Phase, 2010 - 2017
  • 9.5 South and Central America, Clinical Trials by Trial Status, 2010 - 2017
  • 9.6 South and Central America, Clinical Trials by Sponsor Type, 2010 - 2017

10. Western Pacific Glioma Clinical Trial Research Trends:

  • 10.1 Clinical Trials by Top Countries in Western Pacific, 2010 - 2017
  • Western Pacific, Clinical Trials by Country
  • 10.2 Subjects Recruited by Top Countries In Western Pacific, 2010 - 2017
  • Western Pacific, Total Enrolment by Country
  • 10.3 Western Pacific, Clinical Trials by Year, 2010 - 2017
  • 10.4 Western Pacific, Clinical Trials by Development Phase, 2010 - 2017
  • 10.5 Western Pacific, Clinical Trials by Trial Status, 2010 - 2017
  • 10.6 Western Pacific, Clinical Trials by Sponsor Type, 2010 - 2017

11. Recent Clinical Trials - Snapshots:

  • 11.1 Glioma Trial Snapshots - 2018
  • 11.2 Glioma Trial Snapshots - 2017
  • 11.3 Glioma Trial Snapshots - 2016
  • 11.4 Glioma Trial Snapshots - 2015
  • 11.5 Glioma Trial Snapshots - 2014
  • 11.6 Glioma Trial Snapshots - 2013
  • 11.7 Glioma Trial Snapshots - 2012
  • 11.8 Glioma Trial Snapshots - 2011
  • 11.9 Glioma Trial Snapshots - 2010

12 Appendix

  • 12.2 Sources and Research Methodology

1.1. List of Figures:

  • Figure 1: Glioma - Average Enrolment by Country, 2010 - 2017
  • Figure 2: Glioma - Country wise Clinical Trials, 2010 - 2017
  • Figure 3: Glioma - Country wise Recruiting Sites, 2010 - 2017
  • Figure 4: Glioma - Country wise Subjects Recruited, 2010 - 2017
  • Figure 5: Global Glioma Clinical Trials Participation Share by Region, 2010 - 2017
  • Figure 6: Global Glioma Subjects Recruited by Region, 2010 - 2017
  • Figure 7: Global Glioma Clinical Trials by Year, 2010 - 2017
  • Figure 8: Global Glioma Subjects Recruited by Year, 2010 - 2017
  • Figure 9: Global Glioma Trials by Phase, 2010 - 2017
  • Figure 10: Global Glioma - Subjects Recruited by Phase, 2010 - 2017
  • Figure 11: Global Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
  • Figure 12: Global Glioma - Subjects Recruited by Trial Status, 2010 - 2017
  • Figure 13: Global Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
  • Figure 14: Global Glioma - Subjects Recruited by Trial Status, 2010 - 2017
  • Figure 15: Global Glioma - Clinical Trials by Type of Economy, 2010 - 2017
  • Figure 16: Europe Glioma - Country wise Clinical Trials, 2010 - 2017
  • Figure 17: Europe Glioma - Country wise Subjects Recruited, 2010 - 2017
  • Figure 18: Europe Glioma - Year wise Clinical Trials, 2010 - 2017
  • Figure 19: Europe Glioma Trials by Phase, 2010 - 2017
  • Figure 20: Europe Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
  • Figure 21: Europe Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
  • Figure 22: North America Glioma - Country wise Clinical Trials, 2010 - 2017
  • Figure 23: North America Glioma - Country wise Subjects Recruited, 2010 - 2017
  • Figure 24: North America Glioma - Year wise Clinical Trials, 2010 - 2017
  • Figure 25: North America Glioma Trials by Phase, 2010 - 2017
  • Figure 26: North America Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
  • Figure 27: North America Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
  • Figure 28: South and Central America Glioma- Country wise Clinical Trials, 2010 - 2017
  • Figure 29: South and Central America Glioma- Country wise Subjects Recruited, 2010 - 2017
  • Figure 30: South and Central America Glioma- Year wise Clinical Trials, 2010 - 2017
  • Figure 31: South and Central America Glioma Trials by Phase, 2010 - 2017
  • Figure 32: South and Central America Glioma- Clinical Trials by Recruitment Status, 2010 - 2017
  • Figure 33: South and Central America Glioma- Clinical Trials by Sponsor Type, 2010 - 2017
  • Figure 34: Western Pacific Glioma - Country wise Clinical Trials, 2010 - 2017
  • Figure 35: Western Pacific Glioma - Country wise Subjects Recruited, 2010 - 2017
  • Figure 36: Western Pacific Glioma - Year wise Clinical Trials, 2010 - 2017
  • Figure 37: Western Pacific Glioma Trials by Phase, 2010 - 2017
  • Figure 38: Western Pacific Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
  • Figure 39: Western Pacific Glioma - Clinical Trials by Sponsor Type, 2010 - 2017

1.2 List of Tables:

  • Table 1: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 2: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 3: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 4: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 5: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 6: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 7: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 8: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 9: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 10: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 11: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 12: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 13: Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
  • Table 14: Glioma - Region wise Clinical Trials, 2010 - 2017
  • Table 15: Glioma - Region wise Subjects Recruited, 2010 - 2017
  • Table 16: Glioma Trial Snapshots - 2018
  • Table 17: Glioma Trial Snapshots - 2018
  • Table 18: Glioma Trial Snapshots - 2018
  • Table 19: Glioma Trial Snapshots - 2018
  • Table 20: Glioma Trial Snapshots - 2018
  • Table 21: Glioma Trial Snapshots - 2018
  • Table 22: Glioma Trial Snapshots - 2018
  • Table 23: Glioma Trial Snapshots - 2018
  • Table 24: Glioma Trial Snapshots - 2018
  • Table 25: Glioma Trial Snapshots - 2018
  • Table 26: Glioma Trial Snapshots - 2018
  • Table 27: Glioma Trial Snapshots - 2017
  • Table 28: Glioma Trial Snapshots - 2017
  • Table 29: Glioma Trial Snapshots - 2017
  • Table 30: Glioma Trial Snapshots - 2017
  • Table 31: Glioma Trial Snapshots - 2017
  • Table 32: Glioma Trial Snapshots - 2017
  • Table 33: Glioma Trial Snapshots - 2017
  • Table 34: Glioma Trial Snapshots - 2017
  • Table 35: Glioma Trial Snapshots - 2017
  • Table 36: Glioma Trial Snapshots - 2017
  • Table 37: Glioma Trial Snapshots - 2017
  • Table 38: Glioma Trial Snapshots - 2017
  • Table 39: Glioma Trial Snapshots - 2017
  • Table 40: Glioma Trial Snapshots - 2017
  • Table 41: Glioma Trial Snapshots - 2017
  • Table 42: Glioma Trial Snapshots - 2017
  • Table 43: Glioma Trial Snapshots - 2017
  • Table 44: Glioma Trial Snapshots - 2017
  • Table 45: Glioma Trial Snapshots - 2017
  • Table 46: Glioma Trial Snapshots - 2017
  • Table 47: Glioma Trial Snapshots - 2017
  • Table 48: Glioma Trial Snapshots - 2017
  • Table 49: Glioma Trial Snapshots - 2017
  • Table 50: Glioma Trial Snapshots - 2017
  • Table 51: Glioma Trial Snapshots - 2017
  • Table 52: Glioma Trial Snapshots - 2017
  • Table 53: Glioma Trial Snapshots - 2017
  • Table 54: Glioma Trial Snapshots - 2017
  • Table 55: Glioma Trial Snapshots - 2017
  • Table 56: Glioma Trial Snapshots - 2017
  • Table 57: Glioma Trial Snapshots - 2017
  • Table 58: Glioma Trial Snapshots - 2017
  • Table 59: Glioma Trial Snapshots - 2017
  • Table 60: Glioma Trial Snapshots - 2017
  • Table 61: Glioma Trial Snapshots - 2017
  • Table 62: Glioma Trial Snapshots - 2017
  • Table 63: Glioma Trial Snapshots - 2017
  • Table 64: Glioma Trial Snapshots - 2017
  • Table 65: Glioma Trial Snapshots - 2017
  • Table 66: Glioma Trial Snapshots - 2017
  • Table 67: Glioma Trial Snapshots - 2017
  • Table 68: Glioma Trial Snapshots - 2017
  • Table 69: Glioma Trial Snapshots - 2017
  • Table 70: Glioma Trial Snapshots - 2017
  • Table 71: Glioma Trial Snapshots - 2017
  • Table 72: Glioma Trial Snapshots - 2017
  • Table 73: Glioma Trial Snapshots - 2017
  • Table 74: Glioma Trial Snapshots - 2017
  • Table 75: Glioma Trial Snapshots - 2017
  • Table 76: Glioma Trial Snapshots - 2017
  • Table 77: Glioma Trial Snapshots - 2017
  • Table 78: Glioma Trial Snapshots - 2017
  • Table 79: Glioma Trial Snapshots - 2017
  • Table 80: Glioma Trial Snapshots - 2017
  • Table 81: Glioma Trial Snapshots - 2017
  • Table 82: Glioma Trial Snapshots - 2017
  • Table 83: Glioma Trial Snapshots - 2017
  • Table 84: Glioma Trial Snapshots - 2017
  • Table 85: Glioma Trial Snapshots - 2017
  • Table 86: Glioma Trial Snapshots - 2017
  • Table 87: Glioma Trial Snapshots - 2017
  • Table 88: Glioma Trial Snapshots - 2017
  • Table 89: Glioma Trial Snapshots - 2017
  • Table 90: Glioma Trial Snapshots - 2017
  • Table 91: Glioma Trial Snapshots - 2017
  • Table 92: Glioma Trial Snapshots - 2017
  • Table 93: Glioma Trial Snapshots - 2017
  • Table 94: Glioma Trial Snapshots - 2017
  • Table 95: Glioma Trial Snapshots - 2017
  • Table 96: Glioma Trial Snapshots - 2017
  • Table 97: Glioma Trial Snapshots - 2017
  • Table 98: Glioma Trial Snapshots - 2017
  • Table 99: Glioma Trial Snapshots - 2017
  • Table 100: Glioma Trial Snapshots - 2017
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll